Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 58.64 Billion KRW | 77.72% |
| 2022 | 32.99 Billion KRW | 12.84% |
| 2021 | 29.24 Billion KRW | 20.98% |
| 2020 | 24.17 Billion KRW | 7.49% |
| 2019 | 22.48 Billion KRW | 14.7% |
| 2018 | 19.6 Billion KRW | -3.36% |
| 2017 | 20.28 Billion KRW | 7.5% |
| 2016 | 18.87 Billion KRW | 18.33% |
| 2015 | 15.94 Billion KRW | -1.6% |
| 2014 | 16.2 Billion KRW | -26.28% |
| 2013 | 21.98 Billion KRW | -17.79% |
| 2012 | 26.74 Billion KRW | 10.03% |
| 2011 | 24.3 Billion KRW | 186.58% |
| 2010 | 8.48 Billion KRW | -67.83% |
| 2009 | 26.36 Billion KRW | 152.29% |
| 2008 | 10.45 Billion KRW | 9.32% |
| 2007 | 9.56 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.48 Billion KRW | -10.96% |
| 2024 Q1 | 12.89 Billion KRW | -64.35% |
| 2023 Q2 | -12.4 Billion KRW | -219.44% |
| 2023 Q3 | -11.2 Billion KRW | 9.66% |
| 2023 Q4 | 36.18 Billion KRW | 422.8% |
| 2023 FY | 58.64 Billion KRW | 77.72% |
| 2023 Q1 | 10.38 Billion KRW | 6.9% |
| 2022 FY | 32.99 Billion KRW | 12.84% |
| 2022 Q3 | 7.67 Billion KRW | 3.59% |
| 2022 Q4 | 9.71 Billion KRW | 26.61% |
| 2022 Q2 | 7.41 Billion KRW | -9.56% |
| 2022 Q1 | 8.19 Billion KRW | 5.75% |
| 2021 Q1 | 6.49 Billion KRW | -1.0% |
| 2021 Q2 | 7.64 Billion KRW | 17.72% |
| 2021 Q3 | 7.36 Billion KRW | -3.7% |
| 2021 FY | 29.24 Billion KRW | 20.98% |
| 2021 Q4 | 7.74 Billion KRW | 5.27% |
| 2020 Q2 | 6.36 Billion KRW | 0.3% |
| 2020 FY | 24.17 Billion KRW | 7.49% |
| 2020 Q4 | 6.55 Billion KRW | 0.97% |
| 2020 Q3 | 6.49 Billion KRW | 2.1% |
| 2020 Q1 | 6.34 Billion KRW | 0.12% |
| 2019 Q3 | 5.46 Billion KRW | 4.76% |
| 2019 FY | 22.48 Billion KRW | 14.7% |
| 2019 Q2 | 5.21 Billion KRW | -4.69% |
| 2019 Q1 | 5.47 Billion KRW | 13.53% |
| 2019 Q4 | 6.33 Billion KRW | 15.92% |
| 2018 Q3 | 5.03 Billion KRW | 7.63% |
| 2018 FY | 19.6 Billion KRW | -3.36% |
| 2018 Q1 | 5.07 Billion KRW | -4.52% |
| 2018 Q2 | 4.67 Billion KRW | -7.89% |
| 2018 Q4 | 4.82 Billion KRW | -4.21% |
| 2017 Q2 | 5.17 Billion KRW | 1.89% |
| 2017 Q3 | 4.72 Billion KRW | -8.59% |
| 2017 FY | 20.28 Billion KRW | 7.5% |
| 2017 Q1 | 5.07 Billion KRW | 7.63% |
| 2017 Q4 | 5.31 Billion KRW | 12.49% |
| 2016 FY | 18.87 Billion KRW | 18.33% |
| 2016 Q1 | 4.65 Billion KRW | 16.82% |
| 2016 Q4 | 4.71 Billion KRW | -2.93% |
| 2016 Q3 | 4.85 Billion KRW | 4.53% |
| 2016 Q2 | 4.64 Billion KRW | -0.15% |
| 2015 Q2 | 4.02 Billion KRW | 2.04% |
| 2015 Q3 | 4 Billion KRW | -0.41% |
| 2015 FY | 15.94 Billion KRW | -1.6% |
| 2015 Q4 | 3.98 Billion KRW | -0.51% |
| 2015 Q1 | 3.94 Billion KRW | -20.21% |
| 2014 Q2 | 3.72 Billion KRW | 13.3% |
| 2014 Q3 | 4.25 Billion KRW | 14.09% |
| 2014 FY | 16.2 Billion KRW | -26.28% |
| 2014 Q1 | 3.29 Billion KRW | -56.18% |
| 2014 Q4 | 4.93 Billion KRW | 16.13% |
| 2013 Q4 | 7.5 Billion KRW | 94.5% |
| 2013 Q3 | 3.86 Billion KRW | -26.73% |
| 2013 FY | 21.98 Billion KRW | -17.79% |
| 2013 Q1 | 5.34 Billion KRW | -24.09% |
| 2013 Q2 | 5.26 Billion KRW | -1.52% |
| 2012 Q4 | 7.04 Billion KRW | 36.03% |
| 2012 Q1 | 4.83 Billion KRW | 0.0% |
| 2012 Q2 | 9.34 Billion KRW | 93.14% |
| 2012 Q3 | 5.18 Billion KRW | -44.53% |
| 2012 FY | 26.74 Billion KRW | 10.03% |
| 2011 Q1 | 5.63 Billion KRW | 0.0% |
| 2011 Q2 | 5.22 Billion KRW | -7.19% |
| 2011 Q3 | 4.69 Billion KRW | -10.22% |
| 2011 FY | 24.3 Billion KRW | 186.58% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q1 | 5.73 Billion KRW | 10.58% |
| 2010 FY | 8.48 Billion KRW | -67.83% |
| 2010 Q2 | 5 Billion KRW | -12.81% |
| 2009 FY | 26.36 Billion KRW | 152.29% |
| 2009 Q3 | - KRW | -100.0% |
| 2009 Q1 | 3.24 Billion KRW | -7.56% |
| 2009 Q2 | 4.16 Billion KRW | 28.56% |
| 2009 Q4 | 5.19 Billion KRW | 0.0% |
| 2008 Q4 | 3.5 Billion KRW | 0.0% |
| 2008 Q3 | - KRW | -100.0% |
| 2008 FY | 10.45 Billion KRW | 9.32% |
| 2008 Q2 | 1.92 Billion KRW | -16.85% |
| 2008 Q1 | 2.31 Billion KRW | 11.82% |
| 2007 Q3 | 3.54 Billion KRW | 67.66% |
| 2007 Q2 | 2.11 Billion KRW | 4.06% |
| 2007 Q1 | 2.02 Billion KRW | 0.0% |
| 2007 FY | 9.56 Billion KRW | 0.0% |
| 2007 Q4 | 2.07 Billion KRW | -41.48% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -24.105% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 80.32% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 78.938% |
| HANDOK Inc. | 153.76 Billion KRW | 61.862% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 15.271% |
| Yuhan Corporation | 489.94 Billion KRW | 88.03% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 80.895% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -40.333% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 90.401% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 18.531% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 66.325% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -46.416% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 37.313% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 48.883% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -24.105% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -38.078% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 21.859% |
| JW Holdings Corporation | 301.25 Billion KRW | 80.533% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 77.527% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 85.649% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 75.453% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 54.066% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 14.151% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 10.809% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 66.475% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -24.105% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 76.46% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 89.536% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 75.453% |
| Yuhan Corporation | 489.94 Billion KRW | 88.03% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 69.718% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 15.582% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -4.662% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 75.453% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 53.602% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 50.391% |
| CKD Bio Corp. | 25.19 Billion KRW | -132.755% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 73.584% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 64.482% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 11.703% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 54.066% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 83.279% |
| Boryung Corporation | 285.16 Billion KRW | 79.435% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 33.01% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 66.325% |
| JW Lifescience Corporation | 20.26 Billion KRW | -189.436% |